SC14: Liquid Biopsy Technologies and Applications
Room Location: 151

Sunday, March 10 | 5:30-8:30pm

ABOUT THIS COURSE:

Clinical Application of Circulating Cell-Free Tumor DNA

• The scientific background on circulating cell-free tumor DNA (ctDNA)
• Analysis of ctDNA: from sample collection to data generation
• Applications of ctDNA in the clinic and in drug development R&D
• Survey of commercially available ctDNA tests
• Looking into the future: ctDNA as potential companion diagnostics
• Can we combine them: ctDNA, exosomes, and circulating tumor cells?

Adoption Trends and Promising Applications for Liquid Biopsy

• Adoption trends amidst future users
• Predominantly used cell types—CTCs, ctDNA, cfDNA and EVs
• Promising applications for liquid biopsy—current and future
• Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
• Technologies used to detect ctDNA and CTCs—current vs. future users
• Bottleneck to mainstream implementation of liquid biopsy

COURSE AGENDA:

5:30 Clinical Application of Circulating Cell-Free Tumor DNA

6:15 Dinner is served

6:45 Clinical Application of Circulating Cell-Free Tumor DNA (Cont.)

7:00 Adoption Trends and Promising Applications for Liquid Biopsy

8:00 Q&A

8:30 End of Course

INSTRUCTORS:

John Simmons, PhD, Vice President, Translational Medicine, Personal Genome Diagnostics

John Simmons, PhD is the Vice President of Translational Medicine at PGDx. In this role, John focuses broadly on scientific strategy and biomarker discovery and diagnostics development partnerships with pharma/biotech. Previously, John was at the National Cancer Institute where his research focused on identifying novel therapeutic strategies for multiple myeloma through chemical genomic approaches with a particular focus on drug combinations. He received his undergraduate degree in Biology with honors from American University and Ph.D. in Tumor Biology from Georgetown University as part of the NIH Graduate Partnership Program. As a post-doctoral fellow, he received the Multiple Myeloma Research Foundation (MMRF) Research Fellow award to support his work in developing systems-level approaches for drug combination identification and prioritization.

Hatim Husain, MD, Physician, Medical Oncology, University of California, San Diego

Dr Husain received his undergraduate and medical degree from the Northwestern University Feinberg School of Medicine in Chicago, Illinois. He completed his internal medicine residency at the University of Southern California in Los Angeles, and an oncology fellowship at the Johns Hopkins Hospital in Baltimore, Maryland. He has published articles in peer-reviewed journals including Nature Cell Biology, Oncology, Pharmacogenetics, Annals of Oncology, Clinical Cancer Research, Pharmacogenetics and Genomics, the Journal of Neuro-Oncology, and the Journal of Clinical Oncology, among others. His research focuses on novel cancer therapeutic strategies in solid tumors, specifically lung cancer, with an emphasis on the epithelial growth factor receptor and non-invasive cancer detection strategies.

Back To Short Courses